$2500 | Single User
$5000 | Site License
$7500 | Global License

KOL Perspectives: Selective JAK inhibitors in IBD [Report Updated: 05-01-2018]

Published by Global Data: 05 Jan 2018 | 224132 | In Stock

Introduction

KOL Perspectives: Selective JAK inhibitors in IBD

Summary

This KOL Insight briefing focuses on KOLs views of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas -

- Maintenance data for selective JAKs in Crohn’s disease

- Differentiating strategies for selective and non-selective JAKs in IBD

- Choice of primary endpoints for IBD trialsꟷSelective JAKs’ expected efficacy in UC

- Real-world use of JAKs in IBD

Key Highlights

- KOLs were broadly impressed with upadacitinib’s Week 52 data in Crohn’s disease, but views of filgotinib’s Week 20 data were mixed

- Most KOLs stated that upadacitinib maintenance data matched and reinforced positive expectations for upadacitinib in Crohn’s disease

- KOL consensus is that mid-range doses (6/12mg), or extended release equivalents should be used in upadacitinib’s Phase III program.

Scope

- The insight briefing is based on Sociable Pharma’s analysis of primary research with our inflammatory bowel disease key opinion leaders (KOLs)

- In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 N. America-based

- Interviews performed during June 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "selective JAK inhibitors in IBD"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents
for KOL Perspectives: Selective JAK inhibitors in IBD [Report Updated: 05-01-2018]

  • Table of Contents

    Executive Summary

    Background

    Research Panel Composition

    Results & Implications

    Appendix

Additional Details

Publisher

Global Data

Publisher Information

Reference

224132 | GDHC051SP

Number of Pages

26

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
KOL Perspectives: Adaptive Trial Designs in IBD
KOL Perspectives: Adaptive Trial Designs in IBDSummaryThis KOL Insight briefing focuses on KOLs view...
22 Aug 2018 by Global Data USD $2,500 More Info
Biosimilars: European Payer Perspectives (2016)
IntroductionWhat’s driving the uptake of biosimilars in Europe and what still needs to be done?The E...
01 Jan 2016 by FirstWord Pharma USD $2,195 More Info
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeholder & Business Analysis
Antibody-Drug Conjugates 2016: Perspectives & Opportunities - a Pipeline, Technology, Stakeho...
30 Nov 2015 by La Merie USD $500 More Info
Biosimilars: US Payer Perspectives
IntroductionBiosimilars: US Payer Perspectives pulls back the curtain on the US biologics market and...
01 Apr 2015 by FirstWord Pharma USD $2,195 More Info
Harnessing the Power of Patient Support Programmes: pharma, patient and payer perspectives
IntroductionIt all started years ago, with a few patients asking questions on the internet. These da...
01 Apr 2015 by FirstWord Pharma USD $695 More Info
Payer Perspectives on Risk Sharing Deals
IntroductionRisk sharing agreements have been a strategic tool employed for more than a decade. Yet,...
01 Mar 2015 by FirstWord Pharma USD $695 More Info
Biosimilars: European Payer Perspectives
IntroductionCost is king when it comes to European biosimilars. One issue unites European healthca...
06 Jan 2015 by FirstWord Pharma USD $2,195 More Info
Patient Assistance Programs: Payer and Pharma Perspectives
IntroductionPatient assistance programs (PAPs) are evolving in response to increasingly restrictive ...
02 Oct 2014 by FirstWord Pharma USD $695 More Info
Oncology Market Access Europe – Payer and Industry Perspectives
IntroductionOncology Market Access Europe – Payer and Industry Perspectives answers your questions:W...
03 Jul 2014 by FirstWord Pharma USD $995 More Info
Stakeholder Perspectives: Innovation within the Biopharma Industry
IntroductionWhat does innovation mean within the biopharma industry? How much you spend on R&D? How ...
19 Feb 2014 by FirstWord Pharma USD $2,495 More Info

This report is published by Global Data

Download Free Report Summary PDF

KOL Perspectives: Selective JAK inhibitors in IBD [Report Updated: 05-01-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data